Real-World Insights on Tildrakizumab for Plaque Psoriasis: A Meta-Analysis of Four Observational Studies
By
Athanasios Tsianakas
Nina Magnolo
Afra Kempf
Frank Andersohn
Astrid Kirsch
Georgios Kokolakis
Dennis Niebel
March 28, 2026
Clinical Scorecard: Real-World Insights on Tildrakizumab for Plaque Psoriasis: A Meta-Analysis of Four Observational Studies
At a Glance
Category Detail
Condition Moderate-to-severe plaque psoriasis Key Mechanisms Targeting the IL-23/Th17 immune axis via anti-IL-23p19 antibody Target Population Adults with moderate-to-severe plaque psoriasis, including those with high body weight, older patients, and involvement of high-impact areas Care Setting Real-world clinical practice in Germany
Key Highlights
Tildrakizumab shows consistent effectiveness across diverse patient populations. Positive outcomes measured by PASI, BSA, PGA, and DLQI at week 28. Reassurance of treatment reliability in real-world settings. Improvement in quality of life for patients with plaque psoriasis. Meta-analysis synthesizes data from four observational studies. Guideline-Based Recommendations
Diagnosis
Assess psoriasis severity using PASI and PGA. Management
Consider tildrakizumab for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Monitoring & Follow-up
Evaluate treatment effectiveness and safety in real-world conditions. Risks
Monitor for potential adverse effects as per clinical guidelines. Patient & Prescribing Data
Adults with moderate-to-severe plaque psoriasis, including older patients and those with high body weight.
Tildrakizumab demonstrates efficacy and safety in real-world settings, particularly in special populations.
Clinical Best Practices
Utilize real-world data to inform treatment decisions. Monitor patient outcomes regularly to ensure treatment efficacy. Consider individual patient characteristics when prescribing tildrakizumab. References
